In lung cancer, several generations of small-molecular inhibitors have been developed to target the EGFR tyrosine kinases (27), such as inhibitors gefitinib, erlotinib, osimertinib, and necitumumab. The gene discussed is EGFR; the disease is lung carcinoma.